FDA Brief

Warning letters Drugs

FDA warning letter to

Agropharma Laboratories, Inc.

High riskIssued Mar 25, 2022Posted Mar 29, 2022Office of Pharmaceutical Quality Operations, Division II

FDA cited Agropharma Laboratories in Salinas, Puerto Rico, for serious manufacturing violations affecting its OTC antiseptics and hand sanitizers.

What happened

FDA inspected the drug manufacturing facility from October 21 to November 3, 2021, and found broken walls, filth, and pooling water close to open manufacturing equipment. Investigators also found the company had no process validation program and had not shown its water system consistently produces suitable water. FDA said the company's December 6, 2021, response to the inspection findings (Form FDA 483) did not include specific evidence of corrective actions.

What FDA found

  1. The quality unit did not make sure drugs were properly tested and met their specifications.

    21 CFR 211.22
  2. Incoming ingredients were not tested for identity, purity, strength, and other quality attributes.

    21 CFR 211.84(d)(1) and (2)
  3. The production areas were in disrepair, with broken walls, filth, and standing water near open equipment.

    21 CFR 211.56(a)
  4. The company had no process validation and had not shown its water system reliably produces water fit for use.

    21 CFR 211.100(a)
  5. Finished drug products lacked adequate testing and specifications.

    21 CFR 211.165(a)
  6. The company did not follow its stability program or perform annual product reviews.

    21 CFR 211.166(a) and 211.180(e)

What FDA wants

FDA asks the company to respond in writing within 15 working days with corrective actions, a full quality unit remediation plan, a water system assessment and remediation plan, and a risk assessment of affected lots in U.S. distribution, including possible customer notices and recalls. The company must also say whether it plans to resume drug manufacturing and meet with FDA before doing so.

Who should pay attention

  • brands and distributors that bought antiseptics or hand sanitizers from this manufacturer
  • drug companies with similar water systems or facility conditions
  • retailers and healthcare buyers sourcing OTC antiseptics from Puerto Rico

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk